Alexander Schubert
@alexschbrt
Followers
929
Following
637
Media
56
Statuses
549
Helping science companies get funded and started @scifounders Prev: Structure Bio @MRC_LMB, @Cambridge_Uni, @genentech
San Francisco
Joined January 2021
We started collecting applications for SciFounder Fellowship!!. For mission-driven hard tech founders.Up to $1M to get started.Direct mentorship from us for 1 year+.Funding decisions within weeks. Deadline is 2/28 - 11:59 pm PST.
1
8
14
RT @AlexJColville: Scoop: did @Calico, Google's aging moonshot with over $4B invested from its parent co and @AbbVie, just quietly regain t….
0
18
0
The real engine of US biotech isn't big pharma but science-driven startups and they need the most support now. Hopeful not just branding and actions will follow.
The mission to Make America Healthy Again (MAHA) includes MABA — Make American Biotech Accelerate. President Trump showed in his first term what happens when you unlock American science — breakthroughs happen fast. Now, we’re going to do it again. We know the power of U.S.
0
0
1
RT @kulesatony: University budgets everywhere are getting slashed, and we hear many PhD students with accepted ICML papers can no longer af….
0
34
0
RT @AaronDHannon: I’m hiring an #Oncology MD to join Luminate and build the future of cancer care at home as our US Medical Oncology Direct….
0
2
0
Thank you all for tuning in yesterday to our @SciFounders workshop on Biotech Partnerships with @CRISPR_LuCas. We recorded the session for the ones who could not make it. Glad it was helpful for you all!.
0
0
1
RT @SciFounders: Over 700 signups for our workshop on how to secure biotech partnerships with @CRISPR_LuCas. Still time to register!. http….
0
3
0
Some IRR for context. 2015–2020:.• Non-biotech funds: 18.6% IRR (2015–2017), 14.1% (2018–2020).• Biotech funds: 14.1% IRR (2015–2017), 12.8% (2018–2020). 2021–2023:.• Biotech funds: 11.9% IRR.• Non-biotech funds: 0.3% IRR.
1
0
0
Generalists outperformed during the boom, but specialists appear to be holding up better in the current downturn. (still too early to say definitively).
1
0
0
Interesting: the big swings in biotech funding have largely been driven by generalist funds -- many leaned heavily into biotech in 2018–2019 and now seem to be pulling back. Specialist funds have continued deploying at a steadier pace.
1
1
13
RT @CRISPR_LuCas: For all you gene editing scientists out there, I highly encourage you to join this conversation. We've buried our head….
0
2
0
Great post on why Regeneron bought 23andMe and why genetic evidence dramatically increases drug approval success rates (by 2-2.6x!).
0
0
0
Partnerships are becoming more important than ever for biotech startups. @SciFounders is hosting a free, open workshop on how to land partnerships and how to make them work. 350+ sign-ups, but there’s still time to join.
1
1
5
I hope these notes are also a helpful mirror: Am I working on the right thing? Many scientists default to spinning out their own research, but the most compelling companies we've seen came from founders who looked beyond their work.
1
0
0
FINAL THOUGHTS: I hope sharing these patterns helps founders understand how early-stage funds like ours think. The bar is high, but so is our belief in the next generation of technical founders tackling hard problems - and of course, we also get things wrong.
1
0
0
SCIENCE: We are scientists and technical operators ourselves and do like to go deep into the technical bits early on. We like challenging projects if the risk/reward makes sense. Impressed by the scientific rigor and deep know-how of many founders founders we've met.
1
0
0